2,053
Views
2
CrossRef citations to date
0
Altmetric
Health Financing

Cost, healthcare utilization, and outcomes of antibody-mediated rejection in kidney transplant recipients in the US

, , , , &
Pages 1011-1017 | Received 10 May 2021, Accepted 02 Aug 2021, Published online: 18 Aug 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Katharina A. Mayer, Klemens Budde, Bernd Jilma, Konstantin Doberer & Georg A. Böhmig. (2022) Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. Expert Opinion on Emerging Drugs 27:2, pages 151-167.
Read now

Articles from other publishers (1)

Matthew Cooper, Mark Schnitzler, Chanigan Nilubol, Weiying Wang, Zheng Wu & Robert J. Nordyke. (2022) Costs in the Year Following Deceased Donor Kidney Transplantation: Relationships With Renal Function and Graft Failure. Transplant International 35.
Crossref